Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications fo. The mechanisms of barrier dysfunction in irritable bowel syndrome

American Journal of Gastroenterology

Volumn 108, Issue 7, 2013, Pages 1140-1151

  Wilcz Villega, Ewa M ^a   McClean, Siobhán ^b   O'Sullivan, Maria A ^a,c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; CLAUDIN 3; FLUORESCEIN ISOTHIOCYANATE; JUNCTIONAL ADHESION MOLECULE A; NAFAMSTAT MESILATE; OCCLUDIN; PROTEIN ZO1; TRYPTASE; UVOMORULIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; COCULTURE; CONFOCAL MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTESTINE BIOPSY; INTESTINE EPITHELIUM CELL; IRRITABLE COLON; MAST CELL DEGRANULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ABDOMINAL PAIN; ADULT; CACO-2 CELLS; CADHERINS; CELL ADHESION MOLECULES; CLAUDINS; COCULTURE TECHNIQUES; DEXTRANS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; INTERCELLULAR JUNCTIONS; IRRITABLE BOWEL SYNDROME; MALE; MAST CELLS; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; OCCLUDIN; PERMEABILITY; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRYPTASES; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84880235634     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.92     Document Type: Article

References (34)

1. Longstreth GF , Th ompson WG , Chey WD et al. Functional bowel disorders. Gastroenterology 2006 ; 130 : 1480-91.
2. Pichet , Barbara G , Aubert P et al. Impaired intestinal barrier integrity i. The colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009 ; 58 : 196-201.
3. Marshall J , Th abane M , Garg A et al. Intestinal permeability in patients with irritable bowel syndrome aft er a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Th er 2004 ; 20 : 1317-22.
4. Dunlop S , Hebden J , Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006 ; 101 : 1288-94.
5. Maher S , Brayden DJ , Feighery L et al. Crackin. The junction: update o. The progress of gastrointestinal absorption enhancement i. The delivery of poorly absorbed drugs. Crit Rev Th er Drug Carrier Syst 2008 ; 25 : 117-68.
6. Zhou Q , Zhang B , Verne GN. Intestinal membrane permeability and hypersensitivity i. The irritable bowel syndrome. Pain 2009 ; 146 : 41-6.
7. Bertiaux-Vanda ë le N , Youmba SB , Belmonte L. et al. Th e expression an. The cellular distribution of thetight junction proteins are altered in irritable bowel syndrome patients with diff erences according t. The disease subtype. Am J Gastroenterol 2011 ; 106 : 2165-73.
8. Villani A , Lemire M , Th abane M et al. Genetic risk factors for postinfectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010 ; 138 : 1502-13.
9. Laukoetter M , Nava P , Lee W et al. JAM-A regulates permeability and infl ammation i. The intestine in vivo. J Exp Med 2007 ; 204 : 3067-76.
10. Vetrano S , Rescigno M , Cera M et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in infl ammatory bowel disease. Gastroenterology 2008 ; 135 : 173-84.
11. Vetrano S , Danese S. Th e role of JAM-A in infl ammatory bowel disease: unrevealing theties that bind. Ann N Y Acad Sci 2009 ; 1165 : 308-13.
12. O ' Sullivan M , Clayton N , Breslin N et al. Increased mast cells i. The irritable bowel syndrome. Neurogastroenterol Motil 2000 ; 12 : 449-57.
13. Barbara G , Stanghellini V , De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004 ; 126 : 693-702.
14. Park J , Rhee P , Kim H et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006 ; 21 : 71-8.
15. Cremon C , Gargano L , Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009 ; 104 : 392-400.
16. Lee KJ , Kim YB , Kim JH et al. The alteration of enterochromaffi n cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008 ; 23 : 1689-94.
17. Ford AC , Talley NJ. Mucosal infl ammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011 ; 46 : 421-31.
18. Braak B , Klooker TK , Wouters MM et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol 2012 ; 107 : 715-26.
19. Santos J , Yang PC , Sö derholm JD et al. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction i. The rat. Gut 2001 ; 48 : 630-6.
20. Lee J , Park J , Park D et al. Subjects with diarrhea-predominant IBS have increased rectal permeability responsiveto tryptase. Dig Dis Sci 2010.
21. Jacob C , Yang P , Darmoul D et al. Mast cell tryptase controls paracellular permeability o. The intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem 2005 ; 280 : 31936-48.
22. Artursson P , Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coeffi cients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991 ; 175 : 880-5.
23. Mori S , Itoh Y , Shinohata R et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003 ; 92 : 420-3.
24. Isozaki Y , Yoshida N , Kuroda M et al. Anti-tryptasetreatment using nafamostat mesilate has a therapeutic eff ect on experimental colitis. Scand J Gastroenterol 2006 ; 41 : 944-53.
25. Lennard-Jones JE. Classifi cation of infl ammatory bowel disease. Scand J Gastroenterol Suppl 1989 ; 170 : 2 - 6 ; discussion 16-9.
26. Th ompson WG , Longstreth GF , Drossman DA et al. Functional boweldisorders and functional abdominal pain. Gut 1999 ; 45 (Suppl 2) : II43 - 7.
27. Jensen MP , Turner LR , Turner JA et al. The use of multiple-item scales for pain intensity measurement in chronic pain patients. Pain 1996 ; 67 : 35-40.
28. Best WR , Becktel JM , Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 ; 70 : 439-44.
29. Camilleri M , Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007 ; 19 : 545-52.
30. Molino M , Barnathan ES , Numerof R et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997 ; 272 : 4043-9.
31. Kong W , McConalogue K , Khitin LM et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 1997 ; 94 : 8884-9.
32. Mart í nez C , Lobo B , Pigrau M et al. Diarrhea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities i. The jejunal epithelial barrier. Gut 2012.
33. Mart í nez C , Vicario M , Ramos L et al. Th e jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in thetight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 2012.
34. Barbara G , Wang B , Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007 ; 132 : 26-37